Document Detail

Evidence supporting surgery as treatment of choice for acromegaly.
MedLine Citation:
PMID:  9389996     Owner:  NLM     Status:  MEDLINE    
Within a period of fourteen years 531 operations for growth hormone (GH)-secreting adenomas were carried out. In this consecutive series 73% of the 396 patients who underwent primary transsphenoidal surgery achieved basal GH levels below 5 micrograms/l, and 58% also had an adequate suppression following an oral glucose tolerance test (OGTT). Slightly less favourable results were found in patients requiring surgery following an initial therapy. However, 41% of 121 such patients, who had either been operated upon previously or who had received external or internal irradiation, nevertheless achieved basal GH levels below 5 micrograms/l after the surgical reintervention. Normal suppression of serum GH during an OGTT was observed in 23% of these patients. The overall complication rate was low and tumour recurrences were very rare. To facilitate easier tumour removal, octreotide was preoperatively administered in 53 patients undergoing primary surgery of large adenomas. Recurrences were documented in a few exceptional cases. These data support our previous experience that once a normal suppression of growth hormone has been documented following surgery of pituitary adenomas, the long-term outcome is favourable.
R Fahlbusch; J Honegger; M Buchfelder
Related Documents :
17534556 - Outcome of adrenalectomy for cushing's syndrome: experience from a tertiary care center.
25012116 - Adverse outcomes after total and unicompartmental knee replacement in 101 330 matched...
22791766 - Six months of parathyroid hormone (1-84) administered concurrently versus sequentially ...
8989226 - Sandostatin lar in acromegalic patients: long-term treatment.
16950076 - Venaflow plus lovenox vs venaflow plus aspirin for thromboembolic disease prophylaxis i...
24199826 - Timing of early and late seizure recurrence after temporal lobe epilepsy surgery.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of endocrinology     Volume:  155 Suppl 1     ISSN:  0022-0795     ISO Abbreviation:  J. Endocrinol.     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-12-15     Completed Date:  1997-12-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0375363     Medline TA:  J Endocrinol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S53-5     Citation Subset:  IM    
Neurochirurgische Klinik mit Poliklinik, Universität Erlangen-Nürnberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / drug therapy,  etiology,  surgery*
Adenoma / complications,  secretion,  surgery
Combined Modality Therapy
Growth Hormone / secretion
Hormones / therapeutic use
Octreotide / therapeutic use
Pituitary Neoplasms / complications,  secretion,  surgery
Treatment Outcome
Reg. No./Substance:
0/Hormones; 83150-76-9/Octreotide; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly.
Next Document:  Extracellular calmodulin-binding proteins in body fluids of animals.